Pitney Bowes Announces Date for Second Quarter 2026 Earnings Release and Conference Call
Get Alerts PBI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.8%
Revenue Growth %: -1.6%
Join SI Premium – FREE
SHELTON, Conn.--(BUSINESS WIRE)-- Pitney Bowes Inc. (NYSE: PBI), a technology-driven products and services company that provides digital shipping solutions, mailing innovation, and financial services to clients around the world – including more than 90 percent of the Fortune 500 – today announced that it will report second quarter 2026 earnings results after market close on Wednesday, July 29, 2026.
The Company will host an investor conference call the next day on Thursday, July 30, 2026, at 8:00 a.m. ET to review its results. This call and all supplemental information can be accessed on Pitney Bowes’ investor relations site at https://www.investorrelations.pitneybowes.com/.
Pitney Bowes Second Quarter 2026 Financial Results
When: Thursday, July 30, 2026
Time: 8:00 a.m. ET
Conference Call Pre-Registration: Dial-in Link
Webcast: Webcast Link
A recording of the call will also be available on the Company’s website after the call.
About Pitney Bowes
Pitney Bowes (NYSE: PBI) is a technology-driven products and services company that provides digital shipping solutions, mailing innovation, and financial services to clients around the world – including more than 90 percent of the Fortune 500. Small businesses to large enterprises, and government entities rely on Pitney Bowes to reduce the complexity of sending mail and parcels. For the latest news, corporate announcements, and financial results, visit www.pitneybowes.com/us/newsroom. For additional information, visit Pitney Bowes at www.pitneybowes.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716271077/en/
Alex Brown
[email protected]
Source: Pitney Bowes Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
- BNB Price Prediction Heats Up After CFTC Files Crypto Rules, Pepeto Presale Passes $11 Million
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share